Safety and Efficacy of GS-5885/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01768286
First received: January 10, 2013
Last updated: February 27, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2014
  Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)